- Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugsThe study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.BioPharma Dive · 14d ago↗ source
- Draig nets $65M to advance depression drug aimed at rebuilding synapsesDraig Therapeutics has secured $65 million in an oversubscribed Series B raise to advance a pipeline of neuropsychiatry drugs, including its lead depression program designed to modulate the AMPA re…Endpoints · 14d ago↗ source
- Genetic medicine startup Lyora launches with programs from Editas, BiogenLyora Therapeutics will try to revive several early-stage genetic eye disease programs previously held by Editas Medicine and Biogen. The biotech was co-founded by Luk Vandenberghe and Eric Pierce,…